China Health Industries Holdings (CHHE) Cost of Revenue (2017 - 2024)
China Health Industries Holdings (CHHE) has disclosed Cost of Revenue for 13 consecutive years, with $87.0 as the latest value for Q1 2024.
- For the quarter ending Q1 2024, Cost of Revenue fell 99.54% year-over-year to $87.0, compared with a TTM value of $101064.0 through Mar 2024, up 107.43%, and an annual FY2023 reading of $111359.0, up 6270.65% over the prior year.
- Cost of Revenue was $87.0 for Q1 2024 at China Health Industries Holdings, up from $46.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.3 million in Q4 2020 and bottomed at -$14.0 in Q2 2022.
- Average Cost of Revenue over 5 years is $278994.2, with a median of $33972.5 recorded in 2022.
- The sharpest move saw Cost of Revenue plummeted 100.0% in 2022, then skyrocketed 447464.29% in 2023.
- Year by year, Cost of Revenue stood at $1.3 million in 2020, then plummeted by 100.0% to $11.0 in 2021, then surged by 269400.0% to $29645.0 in 2022, then crashed by 99.84% to $46.0 in 2023, then surged by 89.13% to $87.0 in 2024.
- Business Quant data shows Cost of Revenue for CHHE at $87.0 in Q1 2024, $46.0 in Q4 2023, and $38300.0 in Q3 2023.